Cardiac Science's Powerheart gains Australian approval:
This article was originally published in Clinica
The Australian Therapeutic Goods Administration has approved for sale Cardiac Science's automatic hospital bedside defibrillator-monitor, Powerheart. The Irvine, California-based company has signed an exclusive distribution agreement in Australia with CS Australia Pty, which has already resulted in the sale of 50 of the devices, it says. The device was cleared for sale in the US early last year (see Clinica No 894, p 17).
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.